Pre-order Enquiry
Request Free Sample
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Status and Forecast 2019-2025
SKU ID : QYR-14462328 | Publishing Date : 18-Jul-2019 | No. of pages : 99
Request Sample
Request Customization
Check Discounts
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.
In 2018, the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size was 5860 million US$ and it is expected to reach 11500 million US$ by the end of 2025, with a CAGR of 8.8% during 2019-2025.
This report focuses on the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics development in United States, Europe and China.
The key players covered in this study
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
...
Market segment by Type, the product can be split into
Oral Therapy
Injectable Therapy
Market segment by Application, split into
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.
In 2018, the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size was 5860 million US$ and it is expected to reach 11500 million US$ by the end of 2025, with a CAGR of 8.8% during 2019-2025.
This report focuses on the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics development in United States, Europe and China.
The key players covered in this study
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
...
Market segment by Type, the product can be split into
Oral Therapy
Injectable Therapy
Market segment by Application, split into
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
